Trial Profile

A retrospective cohort study to investigate the time to treatment discontinuation and database persistence for patients with first-line metastatic pancreatic cancer treated with nab-paclitaxel and gemcitabine and FOLFIRINOX

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jan 2016 New trial record
22 Jan 2016 Results from this trial were presented at the 2016 ASCO Gastrointestinal Cancers Symposium (ASCO GI), according to a Celgene Corporation media release.
22 Jan 2016 Results published in a Celgene Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com